Can-Fite Biopharma Ltd Sponsored

2.89 USD
-0.48 (-14.24%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Can-Fite Biopharma Ltd Sponsored stock is down -9.97% since 30 days ago. The next earnings date is Aug 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 27.27% of the previous 10 July’s closed higher than June.

About Can-Fite Biopharma Ltd Sponsored

Can-Fite BioPharma Ltd. develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the. treatment of psoriasis; and Phase II clinical trials for COVID-19. It also develops Namodenoson that is in Phase III. trial for. hepatocellular carcinoma, as well as in Phase IIb trial for treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial.